IL‐22‐mediated renal metabolic reprogramming via PFKFB3 to treat kidney injury

IL‐22‐mediated renal metabolic reprogramming via PFKFB3 to treat kidney injury

Abstract Kidney damage initiates the deteriorating metabolic states in tubule cells that lead to the development of end‐stage renal disease (ESTD). Interleukin‐22 (IL‐22) is an effective therapeutic antidote for kidney injury via promoting kidney recovery, but little is known about the underlying mo...

Full description

Bibliographic Details
Main Authors: Wei Chen, Yilan Shen, Jiajun Fan, Xian Zeng, Xuyao Zhang, Jingyun Luan, Yichen Wang, Jinghui Zhang, Si Fang, Xiaobin Mei, Zhen Zhao, Dianwen Ju
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:Clinical and Translational Medicine
Subjects:
interleukin‐22
kidney injury
metabolic reprogramming
mitochondrial dysfunction
Online Access:https://doi.org/10.1002/ctm2.324

Internet

https://doi.org/10.1002/ctm2.324

Similar Items